EP2959894B1 |
12 Oct, 2022
|
S1P Receptor Modulators For Treating Multiple Sclerosis
|
Jun, 2027
|
25
| |
EP3294283B1 |
08 Mar, 2023
|
Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure
|
May, 2036
|
16
| |
EP2228064B1 |
11 Dec, 2019
|
Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor Agonist
|
May, 2025
|
10
| |
EP3351246B8 |
18 Sep, 2019
|
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis
|
Feb, 2022
|
10
| |
EP3342411B1 |
21 Aug, 2019
|
Rapamycin Derivative For Treating Pancreas Cancer
|
Feb, 2022
|
10
| |
EP3038654B1 |
30 Oct, 2019
|
New Use
|
Aug, 2034
|
9
| |
EP2269603B1 |
20 May, 2015
|
Treatment Of Solid Tumours With Rapamycin Derivatives
|
Feb, 2022
|
9
| |
EP2340828B1 |
15 Jul, 2020
|
Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor
|
Nov, 2026
|
8
| |
EP3103448B1 |
03 Jul, 2019
|
Pharmaceutical Compositions Comprising An S1P Modulator
|
Sep, 2027
|
7
| |
EP3143995B1 |
05 Dec, 2018
|
A Rapamycin Derivative For Treating Lung Cancer
|
Feb, 2022
|
7
| |
EP2563906B1 |
08 Nov, 2017
|
Improved Cell Cultivation Process
|
Apr, 2031
|
7
| |
EP3067043B1 |
30 Nov, 2022
|
Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor
|
Nov, 2028
|
6
| |
EP3777834B1 |
16 Feb, 2022
|
Syringe
|
May, 2033
|
6
| |
EP3685826B1 |
03 Nov, 2021
|
Syringe
|
Jan, 2033
|
6
| |
EP3366283B1 |
01 Sep, 2021
|
Direct Compression Formulation And Process
|
Jan, 2025
|
6
| |
EP2887961B1 |
28 Apr, 2021
|
Nep Inhibitors For Treating Diseases Characterized By Atrial Enlargement Or Remodeling
|
Aug, 2033
|
6
| |
EP3330370B1 |
24 Feb, 2021
|
Process For Cultivation Of Cho Cells
|
Apr, 2031
|
6
| |
EP3033086B1 |
22 Sep, 2021
|
Combination Therapy For The Treatment Of Cancer
|
Aug, 2034
|
5
| |
EP2563903B1 |
21 Aug, 2019
|
Improved Cell Culture Medium
|
Apr, 2031
|
5
| |
EP2784084B2 |
04 Oct, 2023
|
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof
|
Jun, 2024
|
4
| |
EP3647783B1 |
21 Dec, 2022
|
Identifying Patient Response To S1P Receptor Modulator Administration
|
Apr, 2033
|
4
| |
EP1983984B1 |
07 Mar, 2018
|
Tuberous Sclerosis Treatment
|
Jan, 2027
|
4
| |
EP2513134B1 |
06 Sep, 2017
|
Wash Solution And Method For Affinity Chromatography
|
Dec, 2030
|
4
| |
EP3023095B2 |
08 Nov, 2023
|
Direct Compression Formulation And Process
|
Jan, 2025
|
3
| |
EP2964202B2 |
31 May, 2023
|
Oral Formulations Of Deferasirox
|
Mar, 2034
|
3
| |
EP3858405B1 |
05 Apr, 2023
|
Syringe
|
May, 2033
|
3
| |
EP3119423B1 |
14 Dec, 2022
|
Treatment Of Cancer Using Chimeric Antigen Receptor
|
Mar, 2035
|
3
| |
EP3283058B1 |
16 Nov, 2022
|
Ribociclib Tablet
|
Apr, 2036
|
3
| |
EP3345602B1 |
06 Apr, 2022
|
Rapamycin Derivative For Treating Advanced Solid Tumours
|
Feb, 2022
|
3
| |
EP3656373B1 |
16 Feb, 2022
|
Syringe
|
Jan, 2033
|
3
| |
EP2892535B1 |
22 Sep, 2021
|
Method Of Adjuvant Cancer Treatment
|
Aug, 2033
|
3
| |
EP3679922B1 |
28 Jul, 2021
|
Syringe
|
May, 2033
|
3
| |
EP3381444B1 |
19 May, 2021
|
Syringe
|
Jan, 2033
|
3
| |
EP3536310B1 |
28 Apr, 2021
|
Syringe
|
May, 2033
|
3
| |
EP3453387B1 |
03 Jun, 2020
|
Dosage Regimen For A S1P Receptor Agonist
|
Dec, 2029
|
3
| |
EP3111954B1 |
03 Apr, 2019
|
Methods Of Treating Ankylosing Spondylitis Or Psoriatic Arthritis Using Anti-Il-17 Antibodies
|
Nov, 2031
|
3
| |
EP2608784B1 |
19 Sep, 2018
|
Treatment Of Hypertension And/Or Prevention Or Treatment Of Heart Failure In A Mammal Receiving Anti-Coagulant Therapy
|
Aug, 2031
|
3
| |
EP3124018B2 |
24 Apr, 2024
|
Oral Formulations Of Deferasirox
|
Mar, 2034
|
2
| |
EP3805248B1 |
18 Jan, 2023
|
Process For Concentration Of Antibodies And Therapeutic Products Thereof
|
Sep, 2025
|
2
| |
EP3560498B1 |
17 Aug, 2022
|
Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
|
Oct, 2030
|
2
| |
EP3541387B1 |
21 Apr, 2021
|
Dose And Regimen For Hdm2-P53 Interaction Inhibitors
|
Nov, 2037
|
2
| |
EP2654736B1 |
01 Jul, 2020
|
Novel Pharmaceutical Composition
|
Dec, 2031
|
2
| |
EP3127427B1 |
08 Jan, 2020
|
Methods Of Administration Of Thrombopoietin Agonist Compounds
|
May, 2030
|
2
| |
EP3409274B1 |
20 Nov, 2019
|
Dosage Regimen For A S1P Receptor Agonist
|
Dec, 2029
|
2
| |
EP2488033B1 |
12 Jun, 2019
|
Combination
|
Oct, 2030
|
2
| |
EP2869813B1 |
21 Nov, 2018
|
Syringe
|
Jan, 2033
|
2
| |
EP3121171B1 |
15 Aug, 2018
|
Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
|
Dec, 2031
|
2
| |
EP2567709B1 |
27 Dec, 2017
|
Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)
|
Oct, 2028
|
2
| |
EP2420223B1 |
19 Jul, 2017
|
Aqueous Pharmaceutical Compositions Containing Borate-Polyol Complexes
|
Mar, 2029
|
2
| |
EP2651918B1 |
12 Jul, 2017
|
Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
|
Dec, 2031
|
2
| |
EP2308466B1 |
31 May, 2017
|
Aqueous Pharmaceutical Compositions Containing Borate-Polyol Complexes
|
Mar, 2029
|
2
| |
EP2214642B1 |
03 May, 2017
|
Topical Composition
|
Oct, 2028
|
2
| |
EP2762140B1 |
22 Mar, 2017
|
Treatment Of Solid Brain Tumours With A Rapamycin Derivative
|
Feb, 2022
|
2
| |
EP3618875B1 |
05 Apr, 2023
|
Combination Therapy
|
Apr, 2038
|
1
| |
EP3738585B1 |
14 Dec, 2022
|
Direct Compression Formulation And Process
|
Jan, 2025
|
1
| |
EP2307457B2 |
22 Jun, 2022
|
Stable And Soluble Antibodies Inhibiting Tnf
|
Jun, 2029
|
1
| |
EP3407945B1 |
04 May, 2022
|
Method For Measuring Flow Features In An Inhaler, Inhaler And System
|
Jan, 2037
|
1
| |
EP3157571B1 |
24 Nov, 2021
|
Fatty Acids And Their Use In Conjugation To Biomolecules
|
Jun, 2035
|
1
| |
EP2971094B1 |
15 Sep, 2021
|
Biomarkers Associated With Brm Inhibition
|
Mar, 2034
|
1
| |
EP3076969B1 |
01 Sep, 2021
|
Dosage Regimen For An Alpha-Isoform Selective Phosphatidylinositol 3-Kinase Inhibitor
|
Dec, 2034
|
1
| |
EP2834246B1 |
28 Jul, 2021
|
Combination Products With Tyrosine Kinase Inhibitors And Their Use
|
Apr, 2033
|
1
| |
EP2970468B1 |
07 Jul, 2021
|
Notch2 Binding Molecules For Treating Respiratory Diseases
|
Mar, 2034
|
1
| |
EP2952177B1 |
20 Jan, 2021
|
Compositions Comprising Sphingosine I Phosphate (Sip) Receptor Modulators
|
Oct, 2028
|
1
| |
EP3172209B1 |
02 Dec, 2020
|
Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide
|
Jul, 2035
|
1
| |
EP3377618B1 |
18 Nov, 2020
|
Buffers For Stabilization Of Lentiviral Preparations
|
Nov, 2036
|
1
| |
EP3160463B1 |
21 Oct, 2020
|
Intermittent Dosing Of Mdm2 Inhibitor
|
Jun, 2035
|
1
| |
EP3199193B1 |
26 Aug, 2020
|
Method For Measuring Flow Features In An Inhaler, Inhaler And System
|
Jan, 2036
|
1
| |
EP3489211B1 |
15 Jul, 2020
|
Improved Methods For Preparing Squalene
|
May, 2031
|
1
| |
EP3045164B1 |
15 Apr, 2020
|
Aqueous Pharmaceutical Compositions Containing Borate-Polyol Complexes
|
Jun, 2030
|
1
| |
EP2820151B1 |
25 Mar, 2020
|
Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation Status
|
Feb, 2033
|
1
| |
EP3340990B1 |
25 Sep, 2019
|
Pharmaceutical Combinations Comprising (A) The Cyclin Dependent Kinase 4/6 (Cdk4/6) Inhibitor Lee011 (=Ribociclib), And (B) The Epidermal Growth Factor Receptor (Egfr) Inhibitor Erlotinib, For The Treatment Or Prevention Of Cancer
|
Aug, 2036
|
1
| |
EP3083677B1 |
28 Aug, 2019
|
Novel Eukaryotic Cells And Methods For Recombinantly Expressing A Product Of Interest
|
Dec, 2034
|
1
| |
EP3083676B1 |
28 Aug, 2019
|
Novel Eukaryotic Cells And Methods For Recombinantly Expressing A Product Of Interest
|
Dec, 2034
|
1
| |
EP2911684B1 |
19 Jun, 2019
|
Il-15R Alpha Forms, Cells Expressing Il-15R Alpha Forms, And Therapeutic Uses Of Il-15R Alpha And Il-15/Il-15R Alpha Complexes
|
Oct, 2033
|
1
| |
EP3137595B1 |
13 Mar, 2019
|
Novel Vertebrate Cells And Methods For Recombinantly Expressing A Polypeptide Of Interest
|
Apr, 2035
|
1
| |
EP2724728B1 |
17 Oct, 2018
|
Complexes Of Il-15 And Il-15R Alpha And Uses Thereof
|
Jun, 2028
|
1
| |
EP2558092B1 |
27 Jun, 2018
|
Combination Comprising A Cyclin Dependent Kinase 4 Or Cyclin Dependent Kinase (Cdk4/6) Inhibitor And An Mtor Inhibitor For Treating Cancer
|
Apr, 2031
|
1
| |
EP2925299B1 |
06 Jun, 2018
|
Novel Pharmaceutical Composition
|
Nov, 2033
|
1
| |
EP2934515B1 |
04 Apr, 2018
|
Pharmaceutical Combination Comprising Binimetinib
|
Dec, 2033
|
1
| |
EP2124547B1 |
28 Mar, 2018
|
Cancer Treatment Method
|
Feb, 2028
|
1
| |
EP2918684B1 |
10 Jan, 2018
|
Rapid Sterility Microassay
|
May, 2030
|
1
| |
EP2908777B1 |
02 Aug, 2017
|
Method And System For Providing An Intraocular Lens Having An Improved Depth Of Field
|
Dec, 2033
|
1
| |
EP2234781B1 |
05 Jul, 2017
|
Method For Cast Molding Contact Lenses
|
Dec, 2028
|
1
| |
EP2783686B1 |
21 Jun, 2017
|
Combination Of A Rapamycin Derivative And Letrozole For Treating Breast Cancer
|
Feb, 2022
|
1
| |